Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbCellera Biologics ( (ABCL) ) has shared an announcement.
On September 10, 2025, AbCellera Biologics announced the appointment of Dr. Sarah Noonberg as its Chief Medical Officer. Dr. Noonberg brings over two decades of experience in clinical development and will play a crucial role in advancing AbCellera’s pipeline of antibody-based therapeutics as the company transitions to a clinical-stage entity. Her previous roles include Chief Medical Officer at Metagenomi and contributions to the development of enzalutamide for prostate cancer at Medivation.
The most recent analyst rating on (ABCL) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on AbCellera Biologics stock, see the ABCL Stock Forecast page.
Spark’s Take on ABCL Stock
According to Spark, TipRanks’ AI Analyst, ABCL is a Neutral.
AbCellera Biologics’ overall score is driven by strong clinical progress and liquidity, but is weighed down by negative profitability, cash flow challenges, and a bearish technical outlook. The strategic shift towards clinical trials offers long-term potential, but near-term financial pressures remain a concern.
To see Spark’s full report on ABCL stock, click here.
More about AbCellera Biologics
AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women’s health, immunology, and oncology.
Average Trading Volume: 6,266,673
Technical Sentiment Signal: Buy
Current Market Cap: $1.25B
For a thorough assessment of ABCL stock, go to TipRanks’ Stock Analysis page.